Pharmaceutical

Eris Lifesciences Q4 profit jumps three-fold to ₹281.6 cr; shares surge 11%

The pharmaceutical company reported robust growth in domestic formulations and insulin franchise performance, while maintaining a strong EBITDA margin of 37 per cent

HAB Pharma targets ₹3,000 crore revenue by 2030 after merger deal

HAB Pharmaceuticals aims to scale operations and expand globally after merging with Signature Phytochemical Industries through a slump sale deal

Strides Pharma Q4FY26 results: Net profit jumps 51% to ₹129 crore

Strides Pharma Science Ltd on Monday reported a 51 per cent rise in consolidated net profit at Rs 129.28 crore for the fourth quarter ended March 31, 2026 driven by a good growth in its main markets excluding the US. The company had posted a profit of Rs 85.62 crore for the year-ago period, Strides Pharma said in a regulatory filing. Revenue from operations in the quarter stood at Rs 1,323.47 crore as compared to Rs 1,190.39 crore in the year-ago period, it added. In the fourth quarter, revenue from main markets excluding the US was up at Rs 645.8 crore as compared to Rs 480 crore in the year-ago period. The US market revenue was at Rs 646.7 crore, down from Rs 651.5 crore in the year-ago period, the company said in an investor presentation. Total expenses in the quarter under review were higher at Rs 1,178.59 crore as compared to Rs 1,071.71 crore in the same period a year ago, the company said. In FY26, consolidated net profit was at Rs 574.52 crore as compared to Rs 3,597.51 cr

Alembic Pharmaceuticals Q4 FY26 results: Net profit rises 29% at ₹202.7 cr

Alembic Pharmaceuticals Ltd on Friday reported a 29 per cent rise in consolidated net profit at Rs 202.7 crore in the fourth quarter ended March 31, driven by revenue growth across segments. The company had posted a consolidated net profit of Rs 156.89 crore in the corresponding period of previous fiscal, Alembic Pharmaceuticals said in a regulatory filing. Consolidated revenue from operations in the fourth quarter stood at Rs 1,847.72 crore as against Rs 1,769.64 crore in the year-ago period, it added. Total expenses in the quarter under review were at Rs 1,730.94 crore as compared to Rs 1,591.22 crore in the same period a year ago, the company said. Alembic Pharmaceuticals Ltd Managing Director Pranav Amin said,"Q4FY26 reflects disciplined execution across our businesses, supported by continued focus on profitability, operational delivery and long-term growth investments." He further said, "We delivered revenue growth across key segments while maintaining healthy pre-R&D ...

India's pharma market grows 10.3% in April on strong chronic performance

India's pharmaceutical market grew 10.3 per cent in April, led by strong demand for anti-diabetes, cardiac and respiratory therapies

Chinese API price surge tests India's pharma buffers amid West Asia crisis

Rising API prices from China and feedstock disruptions amid the West Asia crisis are tightening cost pressures on India's pharma sector despite temporary inventory buffers

Rubicon Research sharpens India play with focus on CNS: CEO Parag Sancheti

Currently, more than 95 per cent of Rubicon's revenue comes from the United States (US), where the company has built a generics and specialty portfolio

Datanomics: Overdependence on China, US plagues India's pharma sector

Govt urges pharma firms to cut import reliance, boost domestic production and diversify exports as data shows rising foreign value addition and heavy dependence on China and the US

Lupin arm settles US antitrust litigation with Humana for $30 million

Lupin says its US subsidiary will pay $30 million to Humana to settle antitrust claims, adding the amount has already been provided for and does not impact current financials

India likely to stay insulated from Trump's tariff shock on patented drugs

US tariffs on patented drugs may have limited immediate impact on India, but industry flags uncertainty as policy ties relief to pricing and manufacturing shifts

Govt permits C3, C4 allocation for pharma, chemicals, and food sectors

A government committee will evaluate sector-wise allocation of C3 and C4 streams for key sectors amid supply constraints and rising energy prices due to the West Asia crisis

Companies eye alternatives after CDSCO bans weight-loss drug ads

Firms may shift to doctor outreach, CME programmes and patient support initiatives as CDSCO bars advertising of GLP-1 drugs ahead of semaglutide patent expiry

Ipca Labs rallies 4%, stock hits 52-week high; analysts see more upside

Ipca Labs hit a 52-week high of ₹1,624 on the BSE in Tuesday's intra-day trade amid heavy volumes and was seen inching towards its record high of ₹1,757.55 touched on January 3, 2025.

India, Uzbekistan launch pharma-nutra corridor; focus on Eurasian market

India and Uzbekistan have launched a policy-backed pharma-nutraceutical corridor to improve regulatory alignment, investment and market access for manufacturers targeting the $7-10 billion Eurasian he

Acutaas zooms 100% in 8 months; what's driving speciality chemicals stock?

Acutaas Chemicals management has revised revenue guidance upwards from 25 per cent to around 30 per cent growth for FY26.

Lupin rallies 12% thus far in CY26, outperforms market; here's why

In the past one month, Lupin has outperformed the market by soaring 6 per cent, as against 4.5 per cent decline in the BSE Sensex.

CDSCO eases NOC norms to speed up clinical research and pharma exports

India's drug regulator is withdrawing export NOC requirements for SRA markets and easing other low-risk approvals, even as it strengthens oversight of manufacturing quality

Sanofi scales up Hyd hub, cements India's role in global pharma GCC play

Sanofi has expanded its Hyderabad Global Capability Centre, raising capacity to 4,500 employees and strengthening India's position as a key hub for R&D, AI, digital innovation

Govt seeks views on exempting 350 medical devices from GTE norms

The pharmaceuticals department has invited stakeholder comments on proposed changes to the list of 350-plus medical devices exempt from GTE rules, with submissions open until February

India-US trade deal: Pharma sees no major change during Section 232 probe

India's pharmaceutical exports to the US are unlikely to see major tariff changes under the interim pact as Section 232 investigations continue, though medical devices may gain from better access